OHLCX Market Research
Delayed

INCY

INCY stands for Incyte Corporation, a biopharmaceutical company focused on developing novel medicines.

−1.96 (−1.69%) Nov 20, 2026 16:05 ET Delayed
Open
113.68
High
117.51
Low
113.68
Prev close
115.87
Volume
2M
Avg vol 10
1M

Today · Market closed · opens Mon 9:30 AM

Price

INCY chart

Updating chart…

Scroll or pinch to zoom, drag to pan, or use the buttons on the chart. About the price history

Signals

Technical analysis

Daily bars · last bar Nov 20, 2026 · close 113.91

Strong sellNeutralStrong buy
Sell
score −0.11 · 18 signalling
3Buy
10Neutral
5Sell

Leaning sell. 5 of 18 signals point down against 3 up, carried by trend. Momentum is mostly neutral. Volatility is mostly neutral. Volume is mostly neutral. Stochastic, Stoch RSI, Williams %R and CCI sit in oversold territory. Trend strength is weak (ADX 11).

How to read this →

Trend

MACD 12, 26, 9
Below signal line and zero
MACD −0.10 · Signal 0.49 · Hist −0.58
Sell
ADX 14
Weak trend, −DI ahead
ADX 11.16 · +DI 17.16 · −DI 24.96
Neutral
Parabolic SAR 0.02, 0.2
Above price, 9.88 over the close
123.79
Sell
Ichimoku 9, 26, 52
Price below cloud, conversion above base
Conv 118.91 · Base 117.48 · A 115.08 · B 119.29
Neutral

Momentum

RSI 14
Mid-range, no extreme
40.50
Neutral
Stoch 14, 3
Oversold, %K still below %D
%K 0.00 · %D 13.65
Neutral
Stoch RSI 14, 14, 3, 3
Oversold, %K still below %D
%K 0.00 · %D 2.53
Neutral
Williams %R 14
Oversold zone, falling
−100.00
Neutral
CCI 14
Below −100, turning up
−197.47
Buy
MFI 14
Below midpoint, not oversold
33.52
Neutral
ROC 12
Price down 7.28% over 12 bars
−7.28%
Sell
AO 5, 35
Above zero, falling
2.17
Neutral
TRIX 18
Just above zero
0.024
Buy
KST 10/15/20/30, 3
Below its signal line
KST 23.92 · Signal 26.59
Sell

Volatility

Bollinger 20, 2
Lower half, %b 0.03
Up 124.08 · Mid 118.81 · Low 113.54
Neutral
Keltner 20, 10, 1.5
Inside the channel, lower half
Up 123.76 · Mid 118.31 · Low 112.85
Neutral

Volume

VWAP 345-bar
Close 12.1% above VWAP
101.60
Buy
Force Index 1
Negative, sellers in control
−3.0M
Sell
ATR
3.67
3.22% of close
A/D Line
16.4M
cumulative
OBV
27.8M
cumulative
Volume Profile
99.88 – 104.56
POC · bull 79.5M · bear 85.4M · 48 / 52
Risk and return

Performance

Daily returns for Jan 1, 2026 – Nov 22, 2026 (YTD). About the returns · About the risk figures

1 month return

-1.97%

Change in value over the past month.

3 month return

-10.43%

Change in value over the last three months.

Max drawdown

18.33%

Largest fall from a peak to the low that followed.

Standard deviation

32.94%

How far daily returns stray from their average, annualised.

Sharpe ratio

0.58

Return above the risk-free rate per unit of volatility.

Calmar ratio

1.04

Annualised return against the maximum drawdown.

About

INCY summary

Loading summary…

Questions

INCY, answered

What is Incyte’s approach to drug development?

Incyte employs a science-driven approach, focusing on molecularly targeted therapies to address unmet medical needs.

What is Incyte’s flagship product?

Incyte’s flagship product is Jakafi (ruxolitinib), used to treat certain types of blood cancer.

When was Incyte founded?

Incyte was founded in 1991 and has been dedicated to oncology and other serious diseases.

How can investors learn more about Incyte?

Investors can visit Incyte’s official website for detailed information on financial performance and corporate updates.

What are Incyte’s primary areas of focus?

Incyte primarily focuses on oncology, hematology, and other unmet medical needs.

What partnerships does Incyte have?

Incyte partners with other pharmaceutical companies and academic institutions to enhance its research capabilities.

How does Incyte contribute to patient communities?

Incyte engages with patient communities to provide support and educational resources about their conditions and treatments.

How does Jakafi work?

Jakafi works by inhibiting specific enzymes involved in cell signaling pathways that contribute to cancer.

What other therapies does Incyte offer?

Incyte offers additional therapies for various conditions, including ruxolitinib for myelofibrosis and graft-versus-host disease.

Does Incyte conduct clinical trials?

Yes, Incyte conducts numerous clinical trials to evaluate the safety and efficacy of its drug candidates.

News

INCY in the news

Optimize Your INCY Trading Now

Elevate your trading strategy with OHLCX execution platform’s sophisticated tools for INCY. Our system integrates cutting-edge technology and expert analysis to support your investment goals. Start optimizing your trades today and explore the benefits of advanced trading now!

Maximize Results Now

Disclaimers

The information displayed on this site is sourced from third-party providers and is believed to be reliable. OHLCX has not independently verified this data and does not guarantee its accuracy. Content is for educational and informational purposes only and is not financial or investment advice.

With any investment, your capital is at risk. Past performance is no guarantee of future results. Consult your provider's terms and privacy policies where applicable.

Prices, charts and every figure derived from them are delayed by at least 15 minutes and are provided for information only; we do not guarantee their accuracy or timeliness.

Securities products are: Not FDIC insured · Not bank guaranteed · May lose value

Trademarks and logos are the property of their respective owners and do not represent endorsements of any kind.